Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director | June 11, 2026 | June 12, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 · Expires 2036-06-11 | Direct | 25,800 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 25,800 · Balance 25,800 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.
Zentalis Pharmaceuticals, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 264,254 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 57,100 · Balance 264,254 F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2029-11-07 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 197,000 · Balance 0 F2: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2029-09-25 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Disposition to issuer · Disposed 1,162,500 · Balance 0 F3: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2030-12-23 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-17 · Disposition to issuer · Disposed 600,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
F2: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
F3: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001838042-26-000003 · wk-form4_1781813319.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,254 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 25,800 | $0.00 Strike: $17.10 | $0.00 |
DisclosureSEC source: 0001193125-26-269378 · ownership.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,800 Underlying: Common Stock · 25,800 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000135 · wk-form4_1750277814.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,154 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-25-086700 · ownership.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2035-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 21:45 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock | 60,000 | $1.72 | $103,446.00 |
DisclosureSEC source: 0001725160-25-000030 · wk-form4_1738705494.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,551 Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 41,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000145 · wk-form4_1719004255.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,551 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:30 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 22,100 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-073063 · ownership.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 20:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,000 | $25.05 | $125,237.50 |
DisclosureSEC source: 0001725160-23-000162 · wk-form4_1694635867.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,970 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023. F2 · balance_after: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 21:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 16,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000141 · wk-form4_1686949276.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,970 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:29 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 20,500 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001209191-23-037355 · doc4.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 20:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001209191-23-021859 · doc4.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 substantially equal monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 11:07 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 36,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000165 · wf-form4_166298085835189.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,606 F1 · shares: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:20 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001104659-21-141737 · tm2133436d14_4seq1.xml · derivative · entry 3 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 600,000 shares Expires 2030-12-23 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:20 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,162,500 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001104659-21-141737 · tm2133436d14_4seq1.xml · derivative · entry 2 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,162,500 shares Expires 2029-09-25 F3 · derivative.exercise_price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:20 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 197,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-21-141737 · tm2133436d14_4seq1.xml · derivative · entry 1 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 197,000 shares Expires 2029-11-07 F2 · derivative.exercise_price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,802 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · derivative · entry 8 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,000 Underlying: Common Shares · 23,802 shares Expires 2029-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. F5 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | SaleCommon Shares | 23,802 | $9.24 | $219,880.50 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · nonDerivative · entry 5 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 23,802 | $0.31 | $7,473.83 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · nonDerivative · entry 4 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,198 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · derivative · entry 7 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,802 Underlying: Common Shares · 19,198 shares Expires 2029-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. F5 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · derivative · entry 6 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162,500 Underlying: Common Shares · 87,500 shares Expires 2029-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. F5 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | SaleCommon Shares | 106,698 | $9.20 | $981,802.99 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · nonDerivative · entry 3 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.36 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 19,198 | $0.31 | $6,028.17 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · nonDerivative · entry 2 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:12 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 87,500 | $0.45 | $39,042.50 |
DisclosureSEC source: 0001062993-21-004511 · form4.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,581 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · derivative · entry 6 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Shares · 19,581 shares Expires 2029-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7916 USD. F6 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | SaleCommon Shares | 19,581 | $15.03 | $294,278.93 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · nonDerivative · entry 4 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 19,581 | $0.43 | $8,370.88 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · nonDerivative · entry 3 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7916 USD. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,419 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · derivative · entry 5 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269,581 Underlying: Common Shares · 5,419 shares Expires 2029-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7867 USD. F6 · derivative.exercise_date: 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | SaleCommon Shares | 5,419 | $15.04 | $81,507.72 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · nonDerivative · entry 2 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:19 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Exercise / conversionCommon Shares | 5,419 | $0.42 | $2,301.99 |
DisclosureSEC source: 0001062993-21-000396 · form4.xml · nonDerivative · entry 1 Skvarka Jan · CIK 0001838042 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7867 USD. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.